Navigation Links
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Date:4/26/2009

thout limitation, statements regarding the timing, progress and results of the clinical development, safety, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
4. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
8. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
9. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ANGELES , Jan. 23, 2015 A lot of ... best methods for treating  certain illnesses, injuries, or conditions. As ... replace previous treatment methods with ones that they consider to ... hernias, there is not one textbook method of treatment that ...
(Date:1/23/2015)... WYNNEWOOD, Pa. , Jan. 23, 2015  MedScope ( ... has been nominated for a 2015 Connected World ... Personal Emergency Response System (mPERS), that can be used ... M2M technology partner.  In nominating MedScope, ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... Kurtz Resigns as President and Chief Executive Officer; Evelyn ... Appointed Acting Chief Executive Officer -, LA JOLLA, Calif., ... announced that Neil Kurtz, M.D., is,resigning as President, Chief Executive ... 31, 2008. Dr. Kurtz is leaving TorreyPines,to assume the role ...
... a San Diego biotech company, developed the first method to ... iron and its distribution in the body. This ... millions of people worldwide such as anemias and iron overload ... the amount of hepcidin in the blood. When levels ...
... Patients and Helps ... Money for Make-A-Wish Foundation, PITTSBURGH, Aug. 8 Aethon ... robot to children,s,hospitals across the country. Also, Aethon will make ... that is deployed. The JR,TUG was initially introduced at the ...
... surgery, pair of studies finds , , FRIDAY, Aug. 8 (HealthDay ... not be accurate for obese men, leaving them more vulnerable ... effective for them, a new pair of studies found. , ... aggressive form of the disease," said Dr. Stephen Freedland, an ...
... Cervical Cancer Screening Participants Receive $15 ... ... Aug. 8 Keystone Mercy Health Plan, the,largest medical assistance ... Inc. (DVCH), a,non-profit organization that provides community-based, primary medical,dental and ...
... the Harvard School of Public Health, today expressed "deep ... Kamiar Alaei, a 2007 Masters of Science graduate of ... The brothers are Iranian physicians working on the prevention ... in their country." , , "There is concern for their ...
Cached Medicine News:Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 2Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 3Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 4Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 5Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 6Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 7Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 3Health News:Obese Men Face Twin Threat From Prostate Cancer 2Health News:Keystone Mercy and DVCH to Offer Screenings for National Health Center Week 2
CMF OL1000 Bone Growth Stimulators are portable, battery-powered medical devices indicated for use in the noninvasive treatment of an established nonunion fracture acquired secondary to trauma, exclu...
... the surgical versatility you demand when treating ... EBI OsteoGen-D offers 40 microamperes of direct ... with 20 microamperes. Available in both Mesh ... flexibility with any of your bone graft ...
... area contact between grant material and fracture ... long bones., ,Grid-Like Format of Mesh Cathode ... Bone , ,The innovative Mesh Cathode of ... area and a scaffolding effect designed to ...
Flowmate makes portable uroflowmetry easy, accurate and dignified. Flowmate has automatic start and stop as well as simple and straightforward reporting from its own printer....
Medicine Products: